Literature DB >> 11890902

Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils.

Maria A Catania1, Maria C Marciano, Alessandra Parisi, Alessio Sturiale, Michele Buemi, Giovanni Grasso, Francesco Squadrito, Achille P Caputi, Gioacchino Calapai.   

Abstract

Erythropoietin has recently been studied for its role in the central nervous system (CNS). It has been shown to exert neuroprotective effects in different models of brain injury. We studied whether neuroprotective effects assessed from the reduction of neuronal loss after transient brain ischemia are associated to the preservation of learning ability. Recombinant human erythropoietin (0.5-25 U) was injected in the lateral cerebral ventricle of gerbils that are subjected to temporary (3 min) bilateral carotid occlusion. Post-ischemic histological evaluation of CA1 area neuronal loss and passive avoidance test were performed. Treatment with recombinant human erythropoietin significantly reduced delayed neuronal death in the CA1 area of the hippocampus and prevented cognition impairment in the passive avoidance test. These data indicate that recombinant human erythropoietin neuroprotective effects in brain ischemia are associated with the preservation of learning function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11890902     DOI: 10.1016/s0014-2999(02)01292-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.

Authors:  Qing-Hui Zhou; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; Ruben J Boado; William M Pardridge
Journal:  Brain Res       Date:  2011-01-26       Impact factor: 3.252

2.  Improved cerebrovascular function and reduced histological damage with darbepoietin alfa administration after cortical impact injury in rats.

Authors:  Leela Cherian; J Clay Goodman; Claudia Robertson
Journal:  J Pharmacol Exp Ther       Date:  2011-01-26       Impact factor: 4.030

Review 3.  Hypoxic preconditioning protects against ischemic brain injury.

Authors:  Frank R Sharp; Ruiqiong Ran; Aigang Lu; Yang Tang; Kenneth I Strauss; Todd Glass; Tim Ardizzone; Myriam Bernaudin
Journal:  NeuroRx       Date:  2004-01

Review 4.  Erythropoietin in stroke therapy: friend or foe.

Authors:  Rhonda Souvenir; Desislava Doycheva; John H Zhang; Jiping Tang
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

5.  Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia.

Authors:  Feng Zhang; Suping Wang; Guodong Cao; Yanqin Gao; Jun Chen
Journal:  Neurobiol Dis       Date:  2006-09-27       Impact factor: 5.996

6.  Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock.

Authors:  Claudia S Robertson; Leela Cherian; Mahek Shah; Robert Garcia; Jovany Cruz Navarro; Raymond J Grill; Carla Cerami Hand; Tian Siva Tian; H Julia Hannay
Journal:  J Neurotrauma       Date:  2011-07-27       Impact factor: 5.269

Review 7.  Does erythropoietin protect the preterm brain?

Authors:  T Strunk; C Härtel; C Schultz
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-07       Impact factor: 5.747

Review 8.  Recent trends in erythropoietin-mediated neuroprotection.

Authors:  Ronald J McPherson; Sandra E Juul
Journal:  Int J Dev Neurosci       Date:  2007-09-04       Impact factor: 2.457

9.  Erythropoietin: recent developments in the treatment of spinal cord injury.

Authors:  Stephana Carelli; Giovanni Marfia; Anna Maria Di Giulio; Giorgio Ghilardi; Alfredo Gorio
Journal:  Neurol Res Int       Date:  2011-07-04

10.  Post-ischemic continuous infusion of erythropoeitin enhances recovery of lost memory function after global cerebral ischemia in the rat.

Authors:  Johan Undén; Carin Sjölund; John-Kalle Länsberg; Tadeusz Wieloch; Karsten Ruscher; Bertil Romner
Journal:  BMC Neurosci       Date:  2013-03-12       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.